EO9 (Apaziquone): from the clinic to the laboratory and back again.

  title={EO9 (Apaziquone): from the clinic to the laboratory and back again.},
  author={Roger M. Phillips and Hans R. Hendriks and Godefridus J. Peters},
  journal={British journal of pharmacology},
  volume={168 1},
EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v. Poor drug delivery to tumours caused by a combination of rapid pharmacokinetic elimination and poor penetration through avascular tissue were the major factors responsible for EO9's poor efficacy. Based upon an understanding of why EO9 failed, a further clinical trial against patients with superficial transitional cell… CONTINUE READING